Home > Dermatology > AAD 2019 > Late-Breakers > Secukinumab maintains improvements in psoriasis through 5 years of treatment

Secukinumab maintains improvements in psoriasis through 5 years of treatment

Presented By
Prof. Richard Langley, Dalhousie University, Canada
Conference
AAD 2019
Trial
ERASURE/FIXTURE

At the 2019 AAD meeting, 5-year follow-up data from the extension cohort of the phase 3 core trials ERASURE/FIXTURE was presented that showed that the IL-17A blocker secukinumab maintains long-term high levels of efficacy[1, 2].

Patients from the ERASURE/FIXTURE trials who gained a 75% response in the Psoriasis Area and Severity Index (PASI) were randomised in 2:1 ratio at week 52 to either the same dose of secukinumab (300 mg/150 mg, continuous-treatment) or placebo (treatment-withdrawal) every 4 weeks, until week 156 or relapse, defined as a >50% reduction in maximal PASI from core study baseline. Patients experiencing relapse with placebo received secukinumab. At week 156, all patients received open-label secukinumab treatment with those on 300 mg continuing 300 mg and those on 150 mg opting to receive 150 mg or 300 mg.

PASI responses were sustained with secukinumab until week 260 (PASI 75/90/100: 85.1%/67.2%/37.8%). “Over 60% of patients were...



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on